Additional file 12. Supplementary discussion.

Additional file 4. Figure S1: Availability of plasma samples. The availability of plasma samples for analysis at each schedule collection time point. Blue and red blocks denote samples collected before and after disease recurrence, respectively. Abbreviations: LUAD – lung adenocarcinoma, LUSC - lung squamous-cell carcinoma, RFS – recurrence-free survival, AT – adjuvant therapy, RT – radiotherapy, LNM – lymph node metastasis.

Additional file 2. Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) Checklist.

Purpose: Understanding the mechanism of brain functional alterations in rectal cancer (RC) patients is of great significance to improve the prognosis and quality of life of patients. Additionally, the influence of chemotherapy on brain function in RC patients is still unclear. In this study, we aimed to investigate the alterations of brain functional network dynamics in RC patients and explore the effects of chemotherapy on temporal dynamics of dynamic functional connectivity (DFC). Methods: The group...

Hamun Lake, the greatest (>8500 km2) freshwater in the Iran plateau, has almost entirely dried over the last 20 years. The flow of the Hirmand (or Helmand) River, the most important feeding river, has decreased from 4.0 to 1.9 km3 in the border of Iran-Afghanistan. In this river basin, the annual water consumption for irrigation is over 90% of the total consumed water. This study aims to calculate the increase in agricultural water consumption in...

Additional file 1: Supplementary Table 1. Motives to exercise by competitive goals in sports. Supplementary Table 2. Motives to exercise by body size perception.

Objective: The effect of antioxidant supplements on glucose metabolism and lipid profiles in polycystic ovary syndrome (PCOS) remains controversial. This systematic review and meta-analysis aimed to evaluate whether antioxidant supplements improve glucose metabolism and lipid profiles in women with PCOS to provide optimal nutritional supplement advice in clinical practice. Methods: The search was conducted across multiple medical databases from inception to January 1, 2022 and performed following the Preferred Reporting Items for Systematic Reviews and...

Additional file 1. Resource use during the first year treatment of Juvenile Idiopathic Arthritis.

Additional file 1: Figure S1. Venn diagram illustrating the number of the variants called by BaseVar, GATK and Bcftools. Figure S2. CLR and Pi analyses in the Angora rabbit population. Figure S3. Q-Q plots for the Angora rabbits. Figure S4. Manhattan plots for the Angora rabbits.

Additional file 6. Figure S3: Prognostic values of postsurgical ctDNA detection at 3 months and 6 months. A-B) The recurrence-free survival analysis (top panel) and multi-variant Cox regression (bottom panel) of postsurgical ctDNA detection at 3 months (A) and 6 months (B). For the analysis at 6 months after surgeries, only patients with plasma samples available at this scheduled point and followed-up for more than 6 months were included. Abbreviations: RFS – recurrence-free survival, LNM...

Additional file 10. Figure S7: Prognostic value of presurgical ctDNA detection. A). The recurrence-free survival analysis of patients stratified by presurgical ctDNA detection. B). The multi-variant Cox regression for presurgical ctDNA detection. Abbreviations: RFS – recurrence-free survival, LNM – lymph node metastasis, LUAD – lung adenocarcinoma, LUSC - lung squamous-cell carcinoma.

Additional file 11. Methods.

Additional file 4. Figure S1: Availability of plasma samples. The availability of plasma samples for analysis at each schedule collection time point. Blue and red blocks denote samples collected before and after disease recurrence, respectively. Abbreviations: LUAD – lung adenocarcinoma, LUSC - lung squamous-cell carcinoma, RFS – recurrence-free survival, AT – adjuvant therapy, RT – radiotherapy, LNM – lymph node metastasis.

Additional file 8. Figure S5: Prognostic values of ctDNA detection based on clonal and subclonal mutations. A). The recurrence-free survival analysis of patients stratified by ctDNA detection based on only clonal mutation profiles. B). The recurrence-free survival analysis of patients stratified by ctDNA detection based on all clonal and subclonal mutations.

Additional file 2. Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) Checklist.

Additional file 1: eFigure1. Flow diagram. eFigure 2. Published studies per medical content area. eFigure 3. Risk of bias per question. eFigure 4. Risk of bias inside intervention categories. eFigure 5. Intervention components in single-component interventions. eMethods 1. Search strategies. eMethods 2. Risk of Bias Tool for RCTs of complex interventions. eMethods 3. Refined version of intervention taxonomy for de-implementation interventions. eMethods 4. Rationale for refined intervention taxonomy. eMethods 5. Rationale for outcome hierarchy of...

BACKGROUND: To evaluate the occurrence of mutations affecting post-translational modification (PTM) sites in matrisome genes across different tumor types, in light of their genomic and functional contexts and in comparison with the rest of the genome. METHODS: This study spans 9075 tumor samples and 32 tumor types from The Cancer Genome Atlas (TCGA) Pan-Cancer cohort and identifies 151,088 non-silent mutations in the coding regions of the matrisome, of which 1811 affecting known sites of hydroxylation,...

Additional file 7. Figure S4: ctDNA statuses and disease-related events of patients during follow-up periods. Swimmer plot illustrating the ctDNA statuses, adjuvant therapies, and pathological events of all patients. Abbreviations: LUAD – lung adenocarcinoma, LUSC - lung squamous-cell carcinoma, AT – adjuvant therapy.

Additional file 5. Figure S2: Mutational profile of plasma samples. Gene mutations detected in tissue and plasma samples in each patient. Colors denote different variant types. Horizontal and vertical bars denote the detection of tissue mutations in presurgical and postsurgical plasma samples, respectively. Twenty most prevalent gene mutations in tissue samples were shown.

Additional file 5. Figure S2: Mutational profile of plasma samples. Gene mutations detected in tissue and plasma samples in each patient. Colors denote different variant types. Horizontal and vertical bars denote the detection of tissue mutations in presurgical and postsurgical plasma samples, respectively. Twenty most prevalent gene mutations in tissue samples were shown.

Additional file 1: eFigure1. Flow diagram. eFigure 2. Published studies per medical content area. eFigure 3. Risk of bias per question. eFigure 4. Risk of bias inside intervention categories. eFigure 5. Intervention components in single-component interventions. eMethods 1. Search strategies. eMethods 2. Risk of Bias Tool for RCTs of complex interventions. eMethods 3. Refined version of intervention taxonomy for de-implementation interventions. eMethods 4. Rationale for refined intervention taxonomy. eMethods 5. Rationale for outcome hierarchy of...

Additional file 1: Supplementary Table 1. Motives to exercise by competitive goals in sports. Supplementary Table 2. Motives to exercise by body size perception.

Additional file 10. Figure S7: Prognostic value of presurgical ctDNA detection. A). The recurrence-free survival analysis of patients stratified by presurgical ctDNA detection. B). The multi-variant Cox regression for presurgical ctDNA detection. Abbreviations: RFS – recurrence-free survival, LNM – lymph node metastasis, LUAD – lung adenocarcinoma, LUSC - lung squamous-cell carcinoma.

Additional file 13. Supplementary results.

Additional file 6. Figure S3: Prognostic values of postsurgical ctDNA detection at 3 months and 6 months. A-B) The recurrence-free survival analysis (top panel) and multi-variant Cox regression (bottom panel) of postsurgical ctDNA detection at 3 months (A) and 6 months (B). For the analysis at 6 months after surgeries, only patients with plasma samples available at this scheduled point and followed-up for more than 6 months were included. Abbreviations: RFS – recurrence-free survival, LNM...